Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors.
Kurukulasuriya, R., Rohde, J.J., Szczepankiewicz, B.G., Basha, F., Lai, C., Jae, H.S., Winn, M., Stewart, K.D., Longenecker, K.L., Lubben, T.W., Ballaron, S.J., Sham, H.L., von Geldern, T.W.(2006) Bioorg Med Chem Lett 16: 6226-6230
- PubMed: 17010607 
- DOI: https://doi.org/10.1016/j.bmcl.2006.09.024
- Primary Citation of Related Structures:  
2I3Z - PubMed Abstract: 
A series of xanthine mimetics containing 5,5 and 5,6 heterocycle fused imidazoles were synthesized as dipeptidyl peptidase IV inhibitors. Compound 7 is potent (h-DPPIV K(i)=2nM) and exhibits excellent selectivity and no species specificity against rat and human enzymes. The X-ray structure confirms that the binding mode of 7 to rat DPPIV is similar to the parent xanthines.
Organizational Affiliation: 
Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6098, USA. ravi.kurukulasuriya@abbott.com